Not available
Quote | Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)
Last: | $2.235 |
---|---|
Change Percent: | 3.47% |
Open: | $2.2 |
Close: | $2.16 |
High: | $2.27 |
Low: | $2.16 |
Volume: | 57,401 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)
2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...
2024-05-31 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is. After all, it’...
Message Board Posts | Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)
Subject | By | Source | When |
---|---|---|---|
Price now | masterofdisaster | investorshub | 05/16/2023 8:15:50 AM |
$CRVS short squeeze | BooDog | investorshub | 05/16/2023 3:50:49 AM |
$CRVS Good read | masterofdisaster | investorshub | 05/15/2023 2:21:46 PM |
$CRVS Price now last trade up | gene_genome | investorshub | 05/14/2023 11:20:05 PM |
$CRVS MomentumIts now up | masterofdisaster | investorshub | 05/14/2023 3:57:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-o...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...